Proprietary Delivery PlatformAdocia’s proprietary drug delivery technologies create a durable competitive asset by improving established therapeutics’ PK profiles. A platform approach can drive repeat licensing, attract pharma partners, and scale across indications, supporting long-term partnership revenue streams.

Strong Recent Revenue GrowthThe very large recent revenue growth figure likely reflects successful collaboration payments or milestones, which validate the company’s science and partner interest. Sustained milestone-based revenue can provide non-dilutive funding and commercial validation over the medium term.

High Gross Profit MarginA relatively high gross margin indicates efficient production-level cost control for formulations. If Adocia commercializes products or licenses them to partners, strong unit economics could support profitability scalability and margins even if operating costs remain elevated.

Bears Say

Negative Shareholders' EquityNegative equity signals structural balance-sheet weakness and limited financial flexibility. It constrains access to traditional financing, increases creditor risk, and can force dilutive capital raises or onerous terms, impairing the company’s ability to sustain long-term development programs.

Negative Operating And Free Cash FlowPersistent negative operating and free cash flow means Adocia depends on financing and partner payments to fund R&D and operations. This reliance creates execution risk, potential dilution, and uncertainty around runway, limiting the company’s ability to independently advance programs.

Persistent Net Losses And Negative MarginsOngoing net losses and negative operating margins reflect an expense base that outpaces revenues. Without sustained revenue from partnerships or successful product commercialization, losses impede reinvestment, heighten fundraising needs, and undermine long-term profitability prospects.

ADOCY FAQ

What was Adocia SA’s price range in the past 12 months?

Adocia SA lowest stock price was $3.56 and its highest was $12.55 in the past 12 months.

What is Adocia SA’s market cap?

Adocia SA’s market cap is $146.96M.

When is Adocia SA’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Adocia SA’s earnings last quarter?

Currently, no data Available

Is Adocia SA overvalued?

According to Wall Street analysts Adocia SA’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Adocia SA pay dividends?

Adocia SA does not currently pay dividends.

What is Adocia SA’s EPS estimate?

Adocia SA’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Adocia SA have?

Adocia SA has 19,607,805 shares outstanding.

What happened to Adocia SA’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Adocia SA?

Currently, no hedge funds are holding shares in ADOCY

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Adocia SA

Adocia SA, a clinical-stage biotechnology company, researches and develops formulations of pre-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. Its proprietary BioChaperone technological platform is designed and developed to optimize the performance of therapeutic proteins. The company's clinical product pipeline includes insulin formulations, such as BioChaperone Lispro U100 and U200, which are ultra-rapid formulations based on rapid insulin lispro; BioChaperone Combo, a combination of acting insulin glargine and rapid-acting insulin lispro; BioChaperone LisPram, a combination of prandial insulin with pramlintide; and BioChaperone Glucagon, an aqueous formulation of human glucagon for the treatment of hypoglycemia, as well as M1Pram, a metabolite of insulin glargine and pramlintide. Its preclinical pipeline includes bi-hormonal products, which include BioChaperone AsPram, which is a combination of rapid insulin aspart with pramlintide; and BioChaperone Glargine Liraglutidea, which is a fixed combination of insulin glargine with an analogue of the GLP-1 receptor. In addition, the company's preclinical pipeline includes multihormonal products for the treatment of obesity, including BioChaperone GluExe, which is a combination of glucagon and exenatide; PramExe, which is a combination of pramlintide and exenatide; and BioChaperone PramGluExe, which is a triple combination of pramlintide, glucagon and exenatide. It has a strategic alliance with Tonghua Dongbao Pharmaceutical Co., Ltd. to develop and commercialize BioChaperone Lispro and BioChaperone Combo in China and other Asian and Middle Eastern territories. The company was incorporated in 2005 and is headquartered in Lyon, France.